Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A

Summary Acquired haemophilia A (AHA) is a rare bleeding disorder caused by autoantibodies against human factor VIII (hFVIII). OBI‐1 is an investigational, B‐domain deleted, recombinant FVIII, porcine sequence, with low cross‐reactivity to anti‐hFVIII antibodies. Efficacy can be monitored with FVIII...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Haemophilia : the official journal of the World Federation of Hemophilia Jg. 21; H. 2; S. 162 - 170
Hauptverfasser:	Kruse-Jarres, R., St-Louis, J., Greist, A., Shapiro, A., Smith, H., Chowdary, P., Drebes, A., Gomperts, E., Bourgeois, C., Mo, M., Novack, A., Farin, H., Ewenstein, B.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England Blackwell Publishing Ltd 01.03.2015 Wiley Subscription Services, Inc
Schlagworte:	acquired haemophilia A Adult Aged Aged, 80 and over Animals Antibodies, Neutralizing Autoantibodies Autoantibodies - immunology Bleeding bleeding episodes Coagulation factors Cross Reactions - immunology Dosage Factor VIII - administration & dosage Factor VIII - adverse effects Factor VIII - immunology Factor VIII - therapeutic use Female Hemophilia Hemophilia A - drug therapy Hemophilia A - immunology Humans Hypersensitivity Male Middle Aged recombinant FVIII porcine sequence Recombinant Proteins - administration & dosage Recombinant Proteins - adverse effects Recombinant Proteins - immunology Recombinant Proteins - therapeutic use replacement therapy Swine Thrombocytopenia Time Factors Treatment Outcome acquired haemophilia A bleeding episodes recombinant FVIII porcine sequence replacement therapy
ISSN:	1351-8216, 1365-2516, 1365-2516
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!